Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach

Abstract excerpt

BACKGROUND: Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor which raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol level, has been documented to increase mortality and cardiac events associated with adverse effects. However, it is still unclear the underlying mechanisms of the off-target effects of torcetrapib. RESULTS: In the present...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Atherosclerosis and Cardiovascular Diseases
• Share to Cardiac Fibrosis and Remodeling
• Share to Histone Deacetylase Inhibitors Research